CMPS•CMPS•Compass Pathways reported positive 26-week Phase 3 COMP360 trial results in nearly 600 treatment-resistant depression patients, confirming rapid, lasting therapeutic effects and consistent safety. Oppenheimer reaffirmed an Outperform rating, citing improved 2027 launch prospects for the synthetic psilocybin therapy and noting the company’s $1.24 billion market capitalization.
Compass Pathways completed a second Phase 3 trial, COMP006, evaluating its COMP360 synthetic psilocybin therapy in almost 600 treatment-resistant depression patients over 26 weeks. The data demonstrated rapid onset of antidepressant effects, durable improvements through the study period and a safety profile consistent with earlier COMP005 results.
Analyst firm Oppenheimer maintained an Outperform rating for Compass Pathways when the stock stood at $12.64, citing the robustness of the new Phase 3 data. The firm highlighted that these results enhance the therapy’s commercial launch prospects and underpin confidence in the company’s strategic roadmap.
Following the trial update and analyst reaffirmation, the stock traded up 0.74% to $12.94, within a 52-week range of $3.34 to $15.40. Trading volume reached approximately 10.54 million shares, and the company’s market capitalization sits at about $1.24 billion.
Long-term efficacy and safety data from COMP006 bolster Compass Pathways’ plan to introduce COMP360 to the market in 2027. The results support regulatory submissions and strengthen investor expectations for the company’s lead asset within its mental health care pipeline.
